AU726799B2 - Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors - Google Patents

Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors Download PDF

Info

Publication number
AU726799B2
AU726799B2 AU46459/97A AU4645997A AU726799B2 AU 726799 B2 AU726799 B2 AU 726799B2 AU 46459/97 A AU46459/97 A AU 46459/97A AU 4645997 A AU4645997 A AU 4645997A AU 726799 B2 AU726799 B2 AU 726799B2
Authority
AU
Australia
Prior art keywords
methyl
propionamide
hydroxy
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU46459/97A
Other languages
English (en)
Other versions
AU4645997A (en
Inventor
Donald E. Harper
Martha A. Warpehoski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of AU4645997A publication Critical patent/AU4645997A/en
Application granted granted Critical
Publication of AU726799B2 publication Critical patent/AU726799B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU46459/97A 1996-09-27 1997-09-19 Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors Ceased AU726799B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2684896P 1996-09-27 1996-09-27
US60/026848 1996-09-27
PCT/US1997/016348 WO1998013340A1 (en) 1996-09-27 1997-09-19 β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS

Publications (2)

Publication Number Publication Date
AU4645997A AU4645997A (en) 1998-04-17
AU726799B2 true AU726799B2 (en) 2000-11-23

Family

ID=21834136

Family Applications (1)

Application Number Title Priority Date Filing Date
AU46459/97A Ceased AU726799B2 (en) 1996-09-27 1997-09-19 Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors

Country Status (21)

Country Link
US (2) US6235928B1 (enExample)
EP (1) EP0929519B1 (enExample)
JP (1) JP2001516338A (enExample)
KR (1) KR20000048639A (enExample)
CN (1) CN1158254C (enExample)
AT (1) ATE289590T1 (enExample)
AU (1) AU726799B2 (enExample)
BR (1) BR9712134A (enExample)
CA (1) CA2266368A1 (enExample)
CZ (1) CZ92399A3 (enExample)
DE (1) DE69732571T2 (enExample)
EA (1) EA001460B1 (enExample)
ES (1) ES2236829T3 (enExample)
HU (1) HUP0000145A3 (enExample)
ID (1) ID21897A (enExample)
IL (1) IL128900A0 (enExample)
NO (1) NO312893B1 (enExample)
NZ (1) NZ334729A (enExample)
PL (1) PL332509A1 (enExample)
UA (1) UA48262C2 (enExample)
WO (1) WO1998013340A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566384B1 (en) * 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
CZ297278B6 (cs) * 1996-08-07 2006-10-11 Darwin Discovery Limited Deriváty hydroxamové a karboxylové kyseliny a jejich pouzití
ID21897A (id) 1996-09-27 1999-08-05 Upjohn Co Asam b-sulfonil hidroksamat sebagai bahan penghambat matriks metaloproteinase
PT960096E (pt) 1997-01-22 2005-08-31 Aventis Pharma Inc Acidos beta-tiocarboxilicos substituidos
GB9702088D0 (en) 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
US6172057B1 (en) * 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
IL131493A (en) * 1997-03-04 2004-05-12 Monsanto Co Aromatic compounds of the hydroxamic sulfonyl alpha-deroxamic acid and their use in the preparation of drugs for the treatment of a condition associated with pathological activity of the metalloprotease matrix
US6187924B1 (en) * 1997-11-12 2001-02-13 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
US6063786A (en) * 1997-11-12 2000-05-16 Darwin Discovery, Ltd. Heterocyclic compounds having MMP and TNF inhibitory activity
PT1037868E (pt) * 1997-11-21 2003-06-30 Upjohn Co Derivados alfa-hidroxi amino e halo de acidos beta-sulfonil-hidroxamicos como inibidores de metaloproteinases matriciais
DE69934094T2 (de) * 1998-01-30 2007-06-06 Darwin Discovery Ltd., Slough N-hydroxyformamid-derivate
EP1357109B1 (en) 1998-06-18 2008-07-23 F. Hoffmann-La Roche Ag Process for aryl alkyl sulfide
GB9916562D0 (en) * 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
US6620823B2 (en) * 2000-07-11 2003-09-16 Bristol-Myers Squibb Pharme Company Lactam metalloprotease inhibitors
GB0017435D0 (en) * 2000-07-14 2000-08-30 Pharmacia & Upjohn Spa 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivatives
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CA2632030A1 (en) 2005-12-15 2007-06-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2008014199A2 (en) * 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 receptor
KR20090069318A (ko) * 2006-09-25 2009-06-30 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 조절하는 화합물
EP2217565B1 (en) * 2007-11-07 2013-05-22 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
EP2326629B1 (en) 2008-07-10 2013-10-02 Boehringer Ingelheim International GmbH Sulfone compounds which modulate the cb2 receptor
CA2737645A1 (en) * 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010147791A1 (en) 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
EP2480544A1 (en) 2009-09-22 2012-08-01 Boehringer Ingelheim International GmbH Compounds which selectively modulate the cb2 receptor
EP2523936A1 (en) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7548296A (en) * 1995-12-20 1997-07-31 Agouron Pharmaceuticals, Inc. Matrix metalloprotease inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB689608A (en) * 1950-04-13 1953-04-01 Basf Ag Improvements in the production of gamma-sulphonyl carboxylic acids
US2659752A (en) * 1951-08-09 1953-11-17 Goodrich Co B F Method for preparing beta-(arylsulfonyl) carboxylic acids and salts thereof
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
US5525629A (en) * 1992-04-07 1996-06-11 British Bio-Technology Limited Inhibition of cytokine production
DE4233099A1 (de) * 1992-10-01 1994-04-07 Hoechst Ag Verfahren zur stereoselektiven Synthese von 3-substituierten 2-Thiomethylpropionsäuren
DE4233100A1 (de) * 1992-10-01 1994-04-07 Hoechst Ag Verfahren zur stereoselektiven Synthese von 3-substituierten 2-Sulfonylmethylpropionsäuren sowie Zwischenprodukte
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
EP0640594A1 (en) * 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
WO1997024117A1 (en) * 1996-01-02 1997-07-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
ID21897A (id) 1996-09-27 1999-08-05 Upjohn Co Asam b-sulfonil hidroksamat sebagai bahan penghambat matriks metaloproteinase
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7548296A (en) * 1995-12-20 1997-07-31 Agouron Pharmaceuticals, Inc. Matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
US5847153A (en) 1998-12-08
CN1230177A (zh) 1999-09-29
IL128900A0 (en) 2000-01-31
NO312893B1 (no) 2002-07-15
CZ92399A3 (cs) 1999-07-14
ID21897A (id) 1999-08-05
WO1998013340A1 (en) 1998-04-02
HK1022468A1 (en) 2000-08-11
EP0929519A1 (en) 1999-07-21
DE69732571D1 (de) 2005-03-31
CN1158254C (zh) 2004-07-21
NZ334729A (en) 2001-01-26
AU4645997A (en) 1998-04-17
EA001460B1 (ru) 2001-04-23
ATE289590T1 (de) 2005-03-15
NO991494L (no) 1999-05-26
CA2266368A1 (en) 1998-04-02
ES2236829T3 (es) 2005-07-16
PL332509A1 (en) 1999-09-13
HUP0000145A3 (en) 2001-12-28
EA199900332A1 (ru) 1999-12-29
DE69732571T2 (de) 2006-01-12
UA48262C2 (uk) 2002-08-15
BR9712134A (pt) 1999-08-31
EP0929519B1 (en) 2005-02-23
NO991494D0 (no) 1999-03-26
HUP0000145A2 (en) 2000-07-28
KR20000048639A (ko) 2000-07-25
US6235928B1 (en) 2001-05-22
JP2001516338A (ja) 2001-09-25

Similar Documents

Publication Publication Date Title
US5847153A (en) β-sulfonyl hydroxamic acids
US6437177B1 (en) α-hydroxy, -amino, and halo derivatives of β-sulfonyl hydroxamic acids as matrix metallopropteinases inhibitors
AU748998B2 (en) N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
JP2002503717A (ja) マトリクス金属プロテイナーゼ阻害薬としてのｎ−ヒドロキシ−２−（アルキル、アリールまたはヘテロアリールスルファニル、スルフィニルまたはスルホニル）−３−置換−アルキル、アリールまたはヘテロアリールアミド
US6765003B1 (en) 3-Arylsulfonyl-2 (substituted methyl) propanoic acid derivatives as matrix metalloproteinase inhibitors
AU776171C (en) Alpha-amino-beta-sulfonyl hydroxamic acid compounds
JP2003519100A (ja) ベータ二置換メタロプロテアーゼ阻害剤
MXPA99002807A (en) &bgr;-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS
MXPA00004937A (en) &agr;-HYDROXY, -AMINO, AND HALO DERIVATIVES OF&bgr;-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS
CZ20001886A3 (cs) Alfa-hydroxy, alfa-amino a alfa-haloderiváty Bsulfonylhydroxamových kyselin jako inhibitory matricových metaloproteináz
CZ20003036A3 (cs) Inhibitory metaloproteinázy matrice

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)